Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of GSK2118436 in previously treated BRAF-mutant metastatic melanoma
2009-015297-36Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib in melanoma, sponsored by GSK. Primary endpoint: Overall response rate. Started Jun 2010; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-015297-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015297-36.